MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026

Definium Therapeutics, Inc.

First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.
Study will enroll ~250 participants at US/European sites; randomized 2:1:2 to 100µg, 50µg, or placebo.
Primary endpoint: change from baseline in HAM-A at Week 12 for MM120 ODT 100µg vs placebo.
Topline data from 12-week double-blind period anticipated in second half of 2026.
Builds on positive Phase 2b results; first Phase 3 study Voyage also recently launched.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.